Print
Editor's Picks
1 2 3 4 5 6 ... » Next
1 2 3 4 5 6 ... » Next
1 2 3 4 5 6 ... » Next
- Sanofi Chief Extends Hand to Bypass Genzyme `Brick Wall'
Bloomberg - U.S. Court Rules Against Obama’s Stem Cell Policy
The New York Times - Takeda Says Lifestyle-Disease Drugs Will Drive Growth
Bloomberg - Study Says Brain Trauma Can Mimic Lou Gehrig’s Disease
The New York Times - Two New Paths to the Dream: Regeneration
The New York Times - Medical Device Makers Face Revamped U.S. Rules for Approvals
Bloomberg - Pfizer May Gain as U.S. Devises Speedy Alternative to Animal Safety Tests
Bloomberg - Judge lets Virginia healthcare challenge proceed
Reuters - F.D.A. Clears Way for Embryonic Stem Cell Trial Using Patients
The New York Times - Technologies Help Adult Children Monitor Aging Parents
The New York Times - Pfizer's Viagra Weighed by U.S. FDA for Children With Rare Lung Disorder
Bloomberg - New Health Official Faces Hostility in Senate
The New York Times - Pharma seeks FDA clarity on risky drug safeguards
Reuters - Special report: Targeting teens for gastric bands
Reuters - Genzyme Said to Rebuff Sanofi-Aventis Takeover Approach; Genzyme Advances
Bloomberg - Sanofi makes approach to Genzyme -sources
Reuters - Sanofi-Aventis’s Biotech Play for Genzyme
The New York Times - U.S. advisers reject Vivus fat-fighting pill
Reuters - PhRMA Names Business Roundtable's Castellani as CEO, Beginning Sept. 1
Bloomberg - Vivus' fat pill works; safety a concern-FDA staff
Reuters - Diabetes Drug Maker Hid Test Data on Risks, Files Indicate
The New York Times - ‘Grim Sleeper’ Arrest Fans Debate on DNA Use
The New York Times - Man-Made Life a Boon That May Draw Terrorists, Scientist Warns
Bloomberg - A pill to make you smarter? Drug grows brain cells
Reuters - Scientists Criticize Study on Genetics of Old Age
The New York Times - F.D.A. Review Disputes Finding That Avandia Is Safe
The New York Times - India Expands Role as Drug Producer
The New York Times - 10,000-plus in U.S. die for lack of cancer screens: CDC
Reuters - Obama makes recess appointment at CMS
The Hill - Genentech culture intact after Roche takeover
Bloomberg Businessweek - Viagra-popping seniors lead the pack for STDs
Reuters - Sanofi Is Said to Plan Major Acquisition in U.S.
Bloomberg - WellPoint seeks new, smaller California rate hike
Reuters - Dendreon Falls After Medicare, Medicaid Begin Analysis of Provenge Drug
Bloomberg - Prostate-Cancer Screening Reduces Deaths by 50%
Bloomberg - Chancellor’s Slip Benefits Tobacco Research
The New York Times - Preparing More Care of Elderly
The New York Times - U.S. FDA panel explores boost for rare drugs
Reuters - Sex and the Single Drug
The New York Times - Prostate Cancer Patients Face Rationing of Provenge
Bloomberg - Bilski Claims Fail As Attempt To Claim “Abstract Idea” – Future Of Business Method Patents Cloudy
patents4Life - Ending the Silence of Generic Drugmakers
Bloomberg Businessweek - Nine in 10 Americans eat too much salt: CDC
Reuters - Ten years on, genomic revolution only just starting
Reuters - U.S. scores dead last again in healthcare study
Reuters - Hazards: Emergencies Over Legal Drugs Increase
The New York Times - Concern Over Foreign Trials for Drugs Sold in U.S.
The New York Times - Obama Says Health Law Shouldn’t Be Excuse to Raise Rates
The New York Times - Research project takes genetics to African roots
Reuters - Now scientists read your mind better than you can
Reuters - Amgen’s Bone Drug Wins Positive Review From U.K. Cost Agency
Bloomberg - Push to Market Pill Stirs Debate on Sexual Desire
The New York Times - Generic-Drug Delay Fight May Be Near ‘Turning Point’ in Court
Bloomberg - The Path to Personalized Medicine
The New England Journal of Medicine - FDA, NIH lay out roadmap for personalized medicine
Reuters - Inexpensive Drug May Save 100,000 Lives a Year After Accidents
Bloomberg - Awaiting the Genome Payoff
The New York Times - A Dirt-Poor Nation, With a Health Plan
The New York Times - Teenage boys really do eat a lot: study
Reuters Health - Drug-resistant bugs on rise globally: report
Reuters - President of J&J’s Unit Said to Have Urged Unpublicized Recall
Bloomberg - U.S. court grants injunction against Dr Reddy's
Reuters - Key cuts to healthcare waste saves $3.6 trillion
Reuters - A Decade Later, Genetic Map Yields Few New
The New York Times - For Forgetful, Cash Helps the Medicine Go Down
The New York Times - Personal Gene Tests From 5 Companies Need FDA
Bloomberg - J&J Knew About Unpublicized Recall, Documents Show
Bloomberg - Bringing Comparison Shopping to the Doctor’s Office
The New York Times - Customs group to fight $200 bln bogus drug industry
Reuters - Drugmakers to share data to speed brain research
Reuters - House panel cites J&J response in recall probe
Reuters - Glaxo’s Revolade Fails to Win Recommendation of U.K. Agency
Bloomberg - Democrats launch push to promote Obama health law
Reuters - Genzyme Says Icahn to Withdraw Slate of Nominees
Bloomberg - Regeneron gout drug works in one trial, fails other
Reuters - Dr. Reddy’s, Cipla May Be Targets, First Global Says
Bloomberg - FDA staff eyes safety of Novartis' MS drug
Reuters - Gates Foundation gives $1.5 bln for women's health
Reuters - Findings May Alter Care for Early Breast Cancer
The New York Times - Nutrition: Study Examines a Diet From TV Ads
The New York Times - Costa Rica puts brakes on popular stem cell tourism
Reuters - Novartis, Sanofi Pursue ‘Cash Machine’ in Indian Countryside
Bloomberg - Grifols Agrees to Buy Talecris for $3 Billion
Bloomberg - SEC charges ex-Sequenom R&D chief with false claims
Reuters - PSA Velocity Predicts Prostate Cancer, Avoids Unneeded Surgery
Bloomberg - Americans prefer drugs for depression: survey
Reuters - Cancer will kill 13.2 million a year by 2030: U.N.
Reuters - Rising Dollar Adds Pressure For US Drug, Device Makers
Dow Jones Newswires - Negative research often spun to look good: study
Reuters - FDA probes hundreds of problems with J&J medicines
Reuters - Icahn to urge removal of Genzyme CEO from board
Reuters - Sinopharm May Buy More Chinese Distributors, Credit Suisse Says
Bloomberg - AstraZeneca Nabs Second Pfizer Executive in R&D Push
Bloomberg - UK doctor at heart of vaccine row banned from practice
Reuters - Families’ Every Fuss, Archived and Analyzed
The New York Times - High-Tech Alternatives to High-Cost Care
The New York Times - GE Spent $700 Million on R&D in First Year of Health Initiative
Bloomberg - Biotech Firms May Get Up to $5 Million Tax Credit
Bloomberg - Is aging a disease?
Reuters - Consumer Gene Tests Investigated by U.S. Lawmakers
Bloomberg
1 2 3 4 5 6 ... » Next
.jpg)
.gif)
.gif)
.png){kind=small}
- Sanofi Chief Extends Hand to Bypass Genzyme `Brick Wall'
Bloomberg - U.S. Court Rules Against Obama’s Stem Cell Policy
The New York Times - Takeda Says Lifestyle-Disease Drugs Will Drive Growth
Bloomberg - Study Says Brain Trauma Can Mimic Lou Gehrig’s Disease
The New York Times - Two New Paths to the Dream: Regeneration
The New York Times - Medical Device Makers Face Revamped U.S. Rules for Approvals
Bloomberg - Pfizer May Gain as U.S. Devises Speedy Alternative to Animal Safety Tests
Bloomberg - Judge lets Virginia healthcare challenge proceed
Reuters - F.D.A. Clears Way for Embryonic Stem Cell Trial Using Patients
The New York Times - Technologies Help Adult Children Monitor Aging Parents
The New York Times